Results 261 to 270 of about 22,609,350 (346)

Cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) tumour expression in gastric carcinoma. [PDF]

Indian J Med Res
Kottarathil MS, D'Cruze L, Dhanabal D, K H.   +3 more
europepmc   +1 more source

Tolerability and efficacy of chemosaturation in combination with systemic therapy for metastatic uveal melanoma

International Journal of Cancer, Volume 159, Issue 2, Page 339-344, 15 July 2026.
What's new? Uveal melanoma is the most common primary intraocular cancer in adults, and up to half of patients develop metastatic disease, predominantly in the liver, where prognosis remains poor despite promising treatment options. In this study, the authors evaluated the safety and efficacy of administering systemic therapy within 40 days of liver ...
Patrick Kasteleiner, Gerd Grözinger, Jörg Schmehl, Lukas Flatz, Andrea Forschner   +4 more
wiley   +1 more source

Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies. [PDF]

Front Immunol
Wang X, He J, Ding G, Tang Y, Wang Q.
europepmc   +1 more source

Clinical Insights Into Hypercalcemia of Malignancy in Childhood

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Hypercalcemia of malignancy (HCM) is a rare but life‐threatening metabolic emergency in children that occurs in less than 1% of pediatric cancer cases, with a reported incidence ranging from 0.4% to 1.0% across different studies. While it is observed in 10%–20% of adult malignancies, pediatric HCM remains relatively uncommon.
Hüseyin Anıl Korkmaz
wiley   +1 more source

Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1. [PDF]

Cancer Discov
Campbell KM, Chen DG, Bustami ZE, Naser Al Deen N, Medina E, Gonzalez CR, Maxey J, Thompson MA, Samorodnitsky S, Kuklinski LF, Perez Garcilazo I, Baselga-Carretero I, Vega-Crespo A, Chen JM, Elumalai R, Visitacion M, Schiemann R, Padron L, Chang C, Zelin AE, Chelluri SS, Boffo S, Kendra KL, Chmielowski B, Truong TG, Khushalani NI, Collichio F, Ikeguchi AP, Victor AI, Margolin KA, Johnson DB, Chen Y, Sosman JA, Patel SP, Hu-Lieskovan S, Moon J, Wells DK, Spencer CN, Bellasea S, Vanderwalde AM, Wu MC, Scumpia PO, Ribas A.   +42 more
europepmc   +1 more source

Engineering Murine Cross‐Reactivity Into an Affibody to Human Death Receptor 5

Biotechnology and Bioengineering, Volume 123, Issue 7, Page 1783-1798, July 2026.
ABSTRACT Interspecies cross‐reactive protein therapeutics that target conserved epitopes across species are critical for translational research. The present study showcases the engineering of an affibody molecule, originally discovered for binding to human death receptor 5 (hDR5) with 94 nM affinity, to simultaneously acquire cross‐reactivity to murine
Tse‐Han Kuo, Nagamani Vunnam, Jonathan N. Sachs, Benjamin J. Hackel   +3 more
wiley   +1 more source

Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer - a brief update. [PDF]

Front Immunol
Park J, Skålhegg BS.
europepmc   +1 more source

Updates on intratumoral therapies in melanoma

Cancer, Volume 132, Issue 13, 1 July 2026.
Abstract Intratumoral therapies provide an opportunity for novel strategies in the management of advanced melanoma. These approaches deliver concentrated doses of therapeutic immune agents directly into individual tumor(s), achieving local tumor control and induction of systemic antitumor immune responses while minimizing the risk of immune‐related ...
Vincent T. Ma, Alyssa K. Steimle, Janmesh D. Patel, Caroline Burkey, Justin C. Moser, Asad Javed, Hibba tul Rehman, Mustafa Ege Seker, Alexander Birbrair, Orhan S. Ozkan, Mark R. Albertini, Yana G. Najjar, Rajan P. Kulkarni   +12 more
wiley   +1 more source

CTLA-4-two pathways to anti-tumour immunity? [PDF]

Immunother Adv
Ward FJ, Kennedy PT, Al-Fatyan F, Dahal LN, Abu-Eid R.   +4 more
europepmc   +1 more source

Indianapolis Consensus Recommendations for Promoting Diversity and Equity in Cancer Clinical Trials: “The Indianapolis Black Paper”

Diversity &Inclusion Research, Volume 3, Issue 3, July 2026.
ABSTRACT Cancer mortality is inequitably distributed across the U.S. and globally, with historically marginalized groups, particularly racial and ethnic minorities, being disproportionately affected. Disproportionate representation in clinical cancer research is a consequence of inequitable access as well as a central factor contributing to outcome ...
Maya N. Birhiray, Andrew Hantel, Joseph R. Mikhael, Kenneth C. Anderson, Ayalew Tefferi, Samuel L. Ranger, Ruemu E. Birhiray, for the Indianapolis Black Paper Group, Sybil Green, Saad Usmani, Mary Owen, Eucharia Borden, Jacqueline Barrientos, Muzzafar Qazilbash, Richard Stone, Rafat Abonour, Coleman Obasaju, Nada Hamad, Irby Hunter, Adrian Barfield, Sandra Garofalo, John Leonard, Martin Tallman   +22 more
wiley   +1 more source